Skip to main content

Biogen Inc.

corporate_fare Company Profile

Biogen Inc.

BIIB·NASDAQ·Life Sciences·CIK 0000875045

Biogen Inc. discovers, develops, manufactures, and delivers therapies across the United States, Europe, Germany, Asia, and internationally. The company offers treatments for multiple sclerosis (MS), including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI. For spinal muscular atrophy, it provides SPINRAZA, and SKYCLARYS is available for Friedreich's Ataxia. QALSODY treats amyotrophic lateral sclerosis, and FUMADERM is used for plaque psoriasis. Biogen also offers biosimilars: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. The company's portfolio includes LEQEMBI for Alzheimer's disease and ZURZUVAE for postpartum depression. Oncology and immunology products include RITUXAN for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA is for non-Hodgkin's lymphoma and CLL, while GAZYVA treats CLL and follicular lymphoma. OCREVUS is available for relapsing MS and primary progressive MS. LUNSUMIO treats relapsed or refractory follicular lymphoma, and glofitamab is for relapsed or refractory diffuse large B-cell lymphoma, alongside other anti-CD20 therapies. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. The company has collaboration and license agreements with various entities, including Merz Therapeutics, Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., UCB, Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis, and Sage Therapeutics, Inc. It also collaborates with Stoke Therapeutics, Inc. for zorevunersen, Dayra Therapeutics, Inc. for oral macrocyclic peptides, Vanqua Bio, Inc. for a preclinical oral C5aR1 antagonist compound, City Therapeutics, Inc. for novel RNAi therapies, and ALTEOGEN Inc. for subcutaneous (SC) formulations of biologics utilizing ALT-B4.

Biogen Inc. (NASDAQ:BIIB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 48 items for BIIB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BIIB spans 10-Q, 8-K.

Recent high-impact activity:

  • Real-World Data Show 76% Slower Alzheimer's Progression on LEQEMBI
  • Diranersen Shows Growing Benefit at Two Years in Early Alzheimer's
  • Biogen's DZP Hits Primary Endpoint in Late-Stage Lupus Trial
  • Biogen 10-Q: Q3 Revenue Up 11% to $2.80B, GAAP EPS $(0.14) on $283.8M IPR&D Charges
  • Biogen Q3 Revenue Up 11% to $2.8B; Low End of FY26 EPS Guidance Raised

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.89B
Net Income
$1.29B
Diluted EPS
$8.79
Op. Cash Flow
$2.2B
Free Cash Flow
$2.05B
Gross Profit
$7.49B
Cash & Equivalents
$3.01B
Total Debt
$0
Debt / Equity
0.00×
Net Margin
13.1%
Shares Outstanding
146.8M sh
Source: 10-K · filed 2026-02-06 · accession 0000875045-26-000013

Short Interest & Short Volume

3.96 days to cover

FINRA reported short interest of 5,453,103 shares in BIIB as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of BIIB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,453,103 shares as of October 30, 2026
Change vs prior period▼ 0.9%
Days to cover3.96 at avg daily volume of 1,376,072
Daily short volume (FINRA facilities)68.4% of 352,134 shares on November 20, 2026
5-day average short volume62.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$249.28 -0.12% today
52-week range · as of 2026-10-28 $138 – $254.41
Market cap
$36.89B
Volume
1.1M (0.9× avg)
3-mo avg 1.2M
Live data · 2026-11-22 03:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $249.28 info
Change: $0 (0%) info
Market Cap: $36.894B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $249.28 info
Change: -$3.72 (-1%) info
Market Cap: $36.894B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $249.28 info
Change: +$0.930 (+0.37%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $249.28 info
Change: +$28.16 (+13%) info
Market Cap: $36.894B info
BIIB
Sep 16, 2026, 2:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $216.17
Real-time Price: $249.28 info
Change: +$33.11 (+15%) info
Market Cap: $36.894B info
BIIB
Aug 31, 2026, 7:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $216.65
Real-time Price: $249.28 info
Change: +$32.63 (+15%) info
Market Cap: $36.894B info
BIIB
Jul 29, 2026, 10:51 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $214.75
Real-time Price: $249.28 info
Change: +$34.54 (+16%) info
Market Cap: $36.894B info
BIIB
Jul 29, 2026, 6:36 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $204.29
Real-time Price: $249.28 info
Change: +$44.99 (+22%) info
Market Cap: $36.894B info
BIIB
Jul 29, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $201.00
Real-time Price: $249.28 info
Change: +$48.28 (+24%) info
Market Cap: $36.894B info
BIIB
Jul 29, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $201.00
Real-time Price: $249.28 info
Change: +$48.28 (+24%) info
Market Cap: $36.894B info
BIIB
Jul 14, 2026, 11:18 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $190.77
Real-time Price: $249.28 info
Change: +$58.51 (+31%) info
Market Cap: $36.894B info
BIIB
Jul 14, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $208.20
Real-time Price: $249.28 info
Change: +$41.08 (+20%) info
Market Cap: $36.894B info
BIIB
Jul 13, 2026, 2:12 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $209.67
Real-time Price: $249.28 info
Change: +$39.62 (+19%) info
Market Cap: $36.894B info
BIIB
Jul 12, 2026, 11:18 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $199.15
Real-time Price: $249.28 info
Change: +$50.13 (+25%) info
Market Cap: $36.894B info
BIIB
Jul 01, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $209.74
Real-time Price: $249.28 info
Change: +$39.54 (+19%) info
Market Cap: $36.894B info
BIIB
Jun 30, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $217.00
Real-time Price: $249.28 info
Change: +$32.28 (+15%) info
Market Cap: $36.894B info
BIIB
Jun 26, 2026, 7:56 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $201.01
Real-time Price: $249.28 info
Change: +$48.27 (+24%) info
Market Cap: $36.894B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets